# Novo Nordisk revenue entity: /record/novo-nordisk.md predicate: revenue page: /record/novo-nordisk/revenue as_of: 2026-11-10 cite: AsOf. "Novo Nordisk revenue: 309,064,000,000 DKK", as of 2025-12-31. Claim clm_8F7EC31D7FFC, https://asof.is/claim/clm_8F7EC31D7FFC, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/353278/000035327826000012/0000353278-26-000012-index.htm. As of November 10, 2026, Novo Nordisk's revenue on the AsOf record is 309.06 billion DKK, dated December 31, 2025, from a primary source (sec.gov). 7 claims on Novo Nordisk's revenue, 1 open and 6 superseded, each dated and sourced; a replaced value is closed with an end date, never deleted. ## Current revenue What the record asserts on 2026-11-10. - [Novo Nordisk](/record/novo-nordisk.md) | revenue | 309,064,000,000 DKK | valid 2025-12-31 to present | conf 0.95 | valid | [clm_8F7EC31D7FFC](/claim/clm_8F7EC31D7FFC.md) sources: https://www.sec.gov/Archives/edgar/data/353278/000035327826000012/0000353278-26-000012-index.htm ## Every dated value One claim per line, oldest first. Superseded claims stay visible. - [Novo Nordisk](/record/novo-nordisk.md) | revenue | 122,021,000,000 DKK | valid 2019-12-31 to 2020-12-31 | conf 0.95 | superseded | superseded_by [clm_67D64D48F06E](/claim/clm_67D64D48F06E.md) | [clm_F0275DE8A21D](/claim/clm_F0275DE8A21D.md) sources: https://www.sec.gov/Archives/edgar/data/353278/000162828022001639/0001628280-22-001639-index.htm - [Novo Nordisk](/record/novo-nordisk.md) | revenue | 126,946,000,000 DKK | valid 2020-12-31 to 2021-12-31 | conf 0.95 | superseded | superseded_by [clm_DEF63B463032](/claim/clm_DEF63B463032.md) | [clm_67D64D48F06E](/claim/clm_67D64D48F06E.md) sources: https://www.sec.gov/Archives/edgar/data/353278/000162828022001639/0001628280-22-001639-index.htm - [Novo Nordisk](/record/novo-nordisk.md) | revenue | 140,800,000,000 DKK | valid 2021-12-31 to 2022-12-31 | conf 0.95 | superseded | superseded_by [clm_459BEEC0AB43](/claim/clm_459BEEC0AB43.md) | [clm_DEF63B463032](/claim/clm_DEF63B463032.md) sources: https://www.sec.gov/Archives/edgar/data/353278/000162828022001639/0001628280-22-001639-index.htm - [Novo Nordisk](/record/novo-nordisk.md) | revenue | 176,954,000,000 DKK | valid 2022-12-31 to 2023-12-31 | conf 0.95 | superseded | superseded_by [clm_8ED842A2DCE7](/claim/clm_8ED842A2DCE7.md) | [clm_459BEEC0AB43](/claim/clm_459BEEC0AB43.md) sources: https://www.sec.gov/Archives/edgar/data/353278/000162828023001868/0001628280-23-001868-index.htm - [Novo Nordisk](/record/novo-nordisk.md) | revenue | 232,261,000,000 DKK | valid 2023-12-31 to 2024-12-31 | conf 0.95 | superseded | superseded_by [clm_A3B9347CE850](/claim/clm_A3B9347CE850.md) | [clm_8ED842A2DCE7](/claim/clm_8ED842A2DCE7.md) sources: https://www.sec.gov/Archives/edgar/data/353278/000162828024002635/0001628280-24-002635-index.htm - [Novo Nordisk](/record/novo-nordisk.md) | revenue | 290,403,000,000 DKK | valid 2024-12-31 to 2025-12-31 | conf 0.95 | superseded | superseded_by [clm_8F7EC31D7FFC](/claim/clm_8F7EC31D7FFC.md) | [clm_A3B9347CE850](/claim/clm_A3B9347CE850.md) sources: https://www.sec.gov/Archives/edgar/data/353278/000162828025003920/0001628280-25-003920-index.htm - [Novo Nordisk](/record/novo-nordisk.md) | revenue | 309,064,000,000 DKK | valid 2025-12-31 to present | conf 0.95 | valid | [clm_8F7EC31D7FFC](/claim/clm_8F7EC31D7FFC.md) sources: https://www.sec.gov/Archives/edgar/data/353278/000035327826000012/0000353278-26-000012-index.htm ## What replaced what - 122.02 billion DKK (2019-12-31 to 2020-12-31, [clm_F0275DE8A21D](/claim/clm_F0275DE8A21D.md)) was replaced by 126.95 billion DKK from 2020-12-31 ([clm_67D64D48F06E](/claim/clm_67D64D48F06E.md)) - 126.95 billion DKK (2020-12-31 to 2021-12-31, [clm_67D64D48F06E](/claim/clm_67D64D48F06E.md)) was replaced by 140.8 billion DKK from 2021-12-31 ([clm_DEF63B463032](/claim/clm_DEF63B463032.md)) - 140.8 billion DKK (2021-12-31 to 2022-12-31, [clm_DEF63B463032](/claim/clm_DEF63B463032.md)) was replaced by 176.95 billion DKK from 2022-12-31 ([clm_459BEEC0AB43](/claim/clm_459BEEC0AB43.md)) - 176.95 billion DKK (2022-12-31 to 2023-12-31, [clm_459BEEC0AB43](/claim/clm_459BEEC0AB43.md)) was replaced by 232.26 billion DKK from 2023-12-31 ([clm_8ED842A2DCE7](/claim/clm_8ED842A2DCE7.md)) - 232.26 billion DKK (2023-12-31 to 2024-12-31, [clm_8ED842A2DCE7](/claim/clm_8ED842A2DCE7.md)) was replaced by 290.4 billion DKK from 2024-12-31 ([clm_A3B9347CE850](/claim/clm_A3B9347CE850.md)) - 290.4 billion DKK (2024-12-31 to 2025-12-31, [clm_A3B9347CE850](/claim/clm_A3B9347CE850.md)) was replaced by 309.06 billion DKK from 2025-12-31 ([clm_8F7EC31D7FFC](/claim/clm_8F7EC31D7FFC.md)) ## Questions this record answers ### What is Novo Nordisk's current revenue? 309.06 billion DKK, dated December 31, 2025, from a primary source (sec.gov). The record asserts this claim as of November 10, 2026 (status valid, confidence 0.95). ### When did Novo Nordisk's revenue last change? The latest value on the record is 309.06 billion DKK, dated December 31, 2025; before it the record holds 290.4 billion DKK, dated December 31, 2024 and closed on December 31, 2025. ### What was Novo Nordisk's revenue before 309.06 billion DKK? 290.4 billion DKK, valid from December 31, 2024 to December 31, 2025 (status superseded), from a primary source (sec.gov). ## Read on - This page: /record/novo-nordisk/revenue (markdown: /record/novo-nordisk/revenue.md) - Entity twin: /record/novo-nordisk.md ยท timeline: /timelines/novo-nordisk.md - Every company's revenue: /facts/revenue.md --- AsOf is a temporal fact ledger: a structured, dated, sourced record of what is true and what changed, built for AI retrieval.